Patents by Inventor Mads Daugaard
Mads Daugaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11787844Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: GrantFiled: February 8, 2013Date of Patent: October 17, 2023Assignee: VAR2 Pharmaceuticals APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20210278406Abstract: The present invention relates to functional binding fragments comprising the minimal CSA-binding fragments of VAR2CSA and their use in identification and isolation of circulating trophoblast and/or fetal cells suitable for non-invasive prenatal diagnostic testing. Thus, the present invention describes methods of identifying and isolating trophoblast and/or fetal cells in a biological sample such as a maternal blood, and utilizing this for prenatal diagnostics.Type: ApplicationFiled: July 12, 2019Publication date: September 9, 2021Inventors: Ali Salanti, Mads Daugaard
-
Patent number: 10675355Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.Type: GrantFiled: December 29, 2014Date of Patent: June 9, 2020Assignees: VAR2 PHARMACEUTICALS APS, ZYMEWORKS INC.Inventors: James R. Rich, John Babcook, Ali El-Salanti, Mads Daugaard, Madeleine Dahlback, Bradley J. Hedberg, Geoffrey C. Winters, Alexander L. Mandel, Elyse Marie Josée Bourque, Tom Han Hsiao Hsieh
-
Publication number: 20200061054Abstract: Methods and compositions employing dianhydrogalactitol or a derivative analog of dianhydrogalactitol together with a p53 modulator, a PARP inhibitor, or topoisomerase inhibitor for treatment of malignancies are provided.Type: ApplicationFiled: February 28, 2018Publication date: February 27, 2020Applicant: Del Mar Pharmaceuticals (BC) Ltd.Inventors: Jeffrey A. Bacha, Dennis M. Brown, Anne Steinø, Mads Daugaard, Beibei Zhai
-
Patent number: 10517958Abstract: VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.Type: GrantFiled: October 4, 2017Date of Patent: December 31, 2019Assignees: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APSInventors: John Babcook, James R. Rich, Mads Daugaard, Ali El-Salanti
-
Publication number: 20190091195Abstract: Substituted hexitol derivatives such as dianhydrogalactitol are useful in the treatment of various neoplastic pathologies. Said pathologies include glioblastoma multiforme, non-small-cell lung carcinoma (NSCLC), ovarian cancer, and leptomeningeal carcinomatosis. The anti-neoplastic activity of dianhydrogalactitol is demonstrated to be due to its activity as an alkylating agent that creates N7 methylation and inter-strand DNA crosslinks. The hexitol derivatives may be used alone or in combination with other anti-neoplastic agents.Type: ApplicationFiled: September 9, 2016Publication date: March 28, 2019Applicant: Del Mar PharmaceuticalsInventors: Jeffrey A. Bacha, Beibei Zhai, Anne Steinø, Mads Daugaard
-
Publication number: 20180193473Abstract: VAR2CSA-drug conjugates for targeting and inhibiting the growth of cancer cells that have developed resistance to a platinum drug and the use of the conjugates in the treatment of platinum drug-resistant cancers. VAR2CSA-drug conjugates (VDCs) comprise a VAR2CSA polypeptide that is capable of binding to oncofetal chondroitin sulfate (ofCS) and one or more toxins having anti-cancer activity conjugated to the VAR2CSA polypeptide, either directly or via a linker.Type: ApplicationFiled: October 4, 2017Publication date: July 12, 2018Inventors: John BABCOOK, James R. RICH, Mads DAUGAARD, Ali EL-SALANTI
-
Publication number: 20180117163Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.Type: ApplicationFiled: December 29, 2014Publication date: May 3, 2018Applicants: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APSInventors: James R. RICH, John BABCOOK, Ali EL-SALANTI, Mads DAUGAARD, Madeleine DAHLBACK, Bradley J. HEDBERG, Geoffrey C. WINTERS, Alexander L. MANDEL, Elyse Marie Josée BOURQUE, Tom Han Hsiao HSIEH
-
Patent number: 9932375Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: GrantFiled: October 5, 2016Date of Patent: April 3, 2018Assignee: VAR2 PHARMACEUTICALS APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Patent number: 9926350Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: GrantFiled: October 5, 2016Date of Patent: March 27, 2018Assignee: VAR2 PHARMACEUTICALS APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20170246310Abstract: VAR2CSA-drug conjugates having biological activity are disclosed. Methods associated with preparation and use of such conjugates, as well as pharmaceutical compositions comprising such conjugates, are also disclosed.Type: ApplicationFiled: December 29, 2014Publication date: August 31, 2017Applicants: ZYMEWORKS INC., VAR2 PHARMACEUTICALS APSInventors: James R. RICH, John BABCOOK, Ali EL-SALANTI, Mads DAUGAARD, Madeleine DAHLBACK, Bradley J. HEDBERG, Geoffrey C. WINTERS, Alexander L. MANDEL, Elyse Marie Josée BOURQUE, Tom Han Hsiao HSIEH
-
Publication number: 20170081373Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: ApplicationFiled: October 5, 2016Publication date: March 23, 2017Applicant: VAR2 PHARMACEUTICAL APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20170016905Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: ApplicationFiled: October 5, 2016Publication date: January 19, 2017Applicant: VAR2 PHARMACEUTICAL APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen
-
Publication number: 20150004099Abstract: The present invention relates to functional binding fragments comprising the minimal binding fragments of VAR2CSA, to antibodies against such binding fragments of VAR2CSA, nucleic acids encoding such fragments of VAR2CSA as well as methods for their production. The invention further relates to conjugates and fusion proteins of VAR2CSA polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate A (CSA), such as an inappropriate expression of chondroitin sulfate A (CSA).Type: ApplicationFiled: February 8, 2013Publication date: January 1, 2015Applicant: VAR2 PHARMACEUTICALS APSInventors: Ali Salanti, Thor Grundtvig Theander, Mads Daugaard, Morten Nielsen, Madeleine Dahlback, Thomas Mandel Clausen